Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.

Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Data privacy startup ID Ward raises €1.1 million to launch its decentralised advertising technology
- 2nd February 2022 11:53 am·
NuVision Biotherapies announces the appointment of its new Chief Executive Officer and Chief Operating Officer
- 13th January 2022 11:43 am·
BlueSkeye AI shortlisted as a finalist for the Medilink Midlands Business Awards 2022
- 17th December 2021 12:40 pm·
University spin-out named best medtech start-up
- 29th November 2021 2:47 pm·
Green jobs at Cheesecake Energy
- 1st November 2021 4:07 pm·
Steve Cliffe joins BlueSkeye AI as it scales the development of its technology and customer portfolio
- 26th October 2021 9:36 am·
Cheesecake Energy announces new board appointments
- 5th October 2021 4:05 pm·
Cheesecake Energy secures £1m seed investment
- 28th September 2021 4:09 pm·
New University spin out to deliver faster and safer engineering maintenance technologies
- 23rd September 2021 1:44 pm·
Locate Bio Closes £10 million Funding Round
- 3rd September 2021 1:33 pm·
Spin-out company launched to deliver wrist device to control Tourette’s
- 9th August 2021 1:03 pm·
Biotech firm that ‘could revolutionise woundcare’ raises £1.8m
- 19th July 2021 3:23 pm·
TextureJet plays a key role in enabling UK manufacturing to Build Back Better
- 1st July 2021 10:12 am·

@OncimmuneECDT on Twitter
#BIO2022 We’re mid-way through the conference and our team is so excited to be back at BIO in person! Awesome sessions and lots of great discussions showcasing Oncimmune’expertise and our platform #ImmunoINSIGHTS #autoantibodies #biomarkers #clinicaltrials #immunooncology
Meet Oncimmune at BIO 2022 in San Diego June 13-16! #BIO2022 #LimitlessTogether https://bit.ly/3ufsmMh
Find our company in the partnering system and schedule a meeting. #ImmunoINSIGHTS #autoantibodies #biomarker #immunebiomarkers #clinicalresearch #immunotherapies #celltherapy
For today’s #FRIDAYREAD we would like to share a publication from @JanssenGlobal on next Generation Natural Killer Cells for Cancer Immunotherapy Published in @FrontImmunol in Immunology
#nkcells #cancerresearch #autoantibodies #biomarkers #immunology

Next Generation Natural Killer Cells for Cancer Immunotherapy
In recent years, immunotherapy for cancer has become mainstream with several products now authorized for therapeutic use in the clinic and are becomin...
bit.ly
In case you missed our #webinar on #autoantibodies as #biomarkers in immune-oncology, download here https://bit.ly/3x8VtlM
#ImmunoINSIGHTS #immunebiomarkers #clinicalresearch #immunotherapy #immunooncology
PUBLICATION #autoantibodies #immunoINSIGHTS
Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection.
#ImmunoINSIGHTS #Biomarkers #immunebiomarkers #clinicalresearch #infectiousdiseases #sarscov2 #covid19

Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection - Journal of Translational Medicine
Background Pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highl...
bit.ly
#ThursdayRead
Removing IL-6 from the mix prevents toxicity and boosts efficacy of checkpoint blockade
#ImmunoINSIGHTS #autoantibodies #Biomarkers #immunebiomarkers #clinicalresearch #immunooncology #checkpointinhibitors

Removing IL-6 from the mix prevents toxicity and boosts efficacy of checkpoint blockade
Immune checkpoint blockade (ICB) has two main limitations: responses vary between subgroups of patients and immune-related adverse events (irAEs) can ...
bit.ly
Interested in #autoantibody profiling?
#ImmunoINSIGHTS™ combines the most comprehensive immunogenic human antigen library + advanced analytics to support your clinical trials
#autoantibodies #immunebiomarkers #biomarkers #immunology #drugdevelopment https://t.co/ZKuXJFlVCf
What if you could access a pivotal class of #biomarkers? Learn why #Bcells and the #autoantibody repertoire is an underestimated #biomarker class to help understand the complex #immune system https://bit.ly/3xSGVas #ImmunoINSIGHTS #autoantibodies